Defilade Capital Management L.P. Makes New $10.68 Million Investment in Oric Pharmaceuticals, Inc. $ORIC

Defilade Capital Management L.P. purchased a new stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) during the 1st quarter, Holdings Channel.com reports. The institutional investor purchased 842,928 shares of the company’s stock, valued at approximately $10,680,000. Oric Pharmaceuticals makes up approximately 1.5% of Defilade Capital Management L.P.’s portfolio, making the stock its 29th largest position.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Federation des caisses Desjardins du Quebec boosted its stake in shares of Oric Pharmaceuticals by 100.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock worth $33,000 after acquiring an additional 2,000 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Oric Pharmaceuticals by 184.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock worth $37,000 after purchasing an additional 2,936 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Oric Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock worth $39,000 after purchasing an additional 977 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of Oric Pharmaceuticals during the third quarter valued at $60,000. Finally, CANADA LIFE ASSURANCE Co purchased a new stake in shares of Oric Pharmaceuticals during the third quarter valued at $65,000. Institutional investors and hedge funds own 95.05% of the company’s stock.

Oric Pharmaceuticals Price Performance

Oric Pharmaceuticals stock opened at $11.07 on Monday. The company’s fifty day simple moving average is $9.72 and its 200-day simple moving average is $10.41. Oric Pharmaceuticals, Inc. has a 12 month low of $7.23 and a 12 month high of $14.93. The stock has a market cap of $1.15 billion, a P/E ratio of -7.69 and a beta of 1.02.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.03). On average, equities research analysts expect that Oric Pharmaceuticals, Inc. will post -1.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Wall Street Zen raised Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. Benchmark reiterated a “buy” rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Oric Pharmaceuticals in a research report on Monday, June 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Friday, July 17th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Oric Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $19.27.

Oric Pharmaceuticals Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.